Европейский рынок лечения CAR-T-клеточной терапией – тенденции отрасли и прогноз до 2028 года

Настройте свой отчет Настройте свой отчет Купить сейчас Купить сейчас Бесплатный пример отчета Бесплатный пример отчета
Дом Pharmaceutical Europe Car T Cell Therapy Treatment Market
Запрос на TOC Запрос на TOC Обратиться к аналитику Обратиться к аналитику Купить сейчас Купить сейчас Узнать перед покупкой Узнать перед покупкой Бесплатный пример отчета Бесплатный пример отчета

Европейский рынок лечения CAR-T-клеточной терапией – тенденции отрасли и прогноз до 2028 года

  • Pharmaceutical
  • Published Report
  • May 2021
  • Europe
  • 350 Pages
  • Количество таблиц: 215
  • Количество рисунков: 51
Купить сейчасКупить сейчас

>Европейский рынок терапии CAR-T-клетками, по продукту (аутологичные CAR-T-клетки, аллогенные CAR-T-клетки), структура (первое поколение CAR-T-клеток, второе поколение Car-T-клеток, третье поколение CAR-T-клеток, четвертое поколение CAR-T-клеток), целевые антигены (антигены солидных опухолей, антигены гематологических злокачественных новообразований и другие), бренд (Yescarta, Kymriah, Tecartus и другие), терапевтическое применение (гематологические злокачественные новообразования, рак поджелудочной железы, рак молочной железы, рак легких, рак желудка, множественная миелома, хронический лимфоцитарный лейкоз, мантийноклеточная лимфома, фолликулярная лимфома, диффузная крупноклеточная В-клеточная лимфома, острый лимфобластный лейкоз и другие), конечный пользователь (больницы, специализированные клиники и другие), канал сбыта (Больницы, аптеки, другие), Страна (Германия, Великобритания, Франция, Италия, Испания, Нидерланды, Россия, Швейцария, Турция, Австрия, Норвегия, Венгрия, Литва, Ирландия, Польша, остальные страны Европы) Тенденции отрасли и прогноз до 2028 года

Европейский рынок лечения CAR-T-клеточной терапией

Анализ рынка и аналитика : Европейский рынок лечения CAR-T-клеточной терапией

Ожидается, что рынок лечения с помощью CAR-T-клеточной терапии будет расти в прогнозируемый период с 2021 по 2028 год. По данным Data Bridge Market Research, рынок растет со среднегодовым темпом роста 29,4% в прогнозируемый период с 2021 по 2028 год и, как ожидается, достигнет 10 594,65 млн долларов США к 2028 году. Рост использования CAR-T-клеточной терапии для лечения рака и инфекционных заболеваний выступает в качестве драйвера роста рынка лечения с помощью CAR-T-клеточной терапии.

Терапия CAR-T-клеток или химерные антигенные рецепторы Т-клеток — это те Т-клетки , которые генетически модифицированы для получения искусственного Т-клеточного рецептора, который может использоваться в качестве иммунотерапии для лечения различных видов рака. Химерные антигенные рецепторы — это те рецепторные белки, которые были модифицированы в лабораториях для предоставления Т-клеткам новой способности нацеливаться на определенный белок.

Рост осведомленности об иммунотерапии привел к тому, что люди столкнулись с несколькими видами терапии CAR-T и их эффективностью, и, следовательно, выступает в качестве драйвера для рынка лечения клеточной терапией CAR-T. Неблагоприятные побочные эффекты терапии ограничивают выбор некоторых групп населения таким лечением, что влияет на стоимость продукта и, следовательно, выступает в качестве сдерживающего фактора для роста рынка лечения клеточной терапией CAR-T. Наличие линейки продуктов предполагает, что участники рынка постоянно занимаются производством инновационных лекарств, поэтому выступает в качестве возможности для рынка лечения клеточной терапией CAR-T. Длительное время одобрения иммунотерапии ограничивает производителя продукта в получении потенциальной выгоды на рынке и влияет на общий размер рынка, следовательно, выступает в качестве проблемы для роста рынка лечения клеточной терапией CAR-T.

The CAR-T cell therapy treatment market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an analyst brief, our team will help you create a revenue impact solution to achieve your desired goal.

Европейский рынок лечения CAR-T-клеточной терапией

Europe CAR-T Cell Therapy Treatment Market Scope and Market Size

The CAR-T cell therapy treatment market is segmented on the basis of the product, structure, targeted antigens, brand, therapeutic application, end user and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

  • On the basis of product, the CAR-T cell therapy treatment market is segmented into autologous CAR-T cells and allogeneic CAR-T cells. In 2021, autologous CAR-T cells segment is expected to dominate the CAR-T cell therapy treatment market because the drugs approved for CAR-T cell therapy are autologous in nature.
  • On the basis of structure, the CAR-T cell therapy treatment market is segmented into first generation CAR-T cells, second generation CAR-T cells, third generation CAR-T cells and fourth generation CAR-T cells. In 2021, second generation CAR-T cells segment is expected to dominate the CAR-T cell therapy treatment market because the approved therapies are second generation based structure.
  • On the basis of targeted antigens, the CAR-T cell therapy treatment market is segmented into antigens on solid tumors, antigens on hematologic malignancies and others. In 2021, antigens on hematologic malignancies segment is expected to dominate the CAR-T cell therapy treatment market because drugs approved for CAR-T cell therapy are majorly used for hematologic malignancies and ongoing extensive research development. 
  • On the basis of brand, the CAR-T cell therapy treatment market is segmented into yescarta, kymriah, tecartus and others. In 2021, yescarta segment is expected to dominate the CAR-T cell therapy treatment market because yescarta is the first approved CAR-T cell therapy for oncology therapeutic class. 
  • On the basis of therapeutic application, the CAR-T cell therapy treatment market is segmented into hematological malignancies, pancreatic cancer, breast cancer, lung cancer, gastric cancer, multiple myeloma, chronic lymphocytic leukemia, mantle cell lymphoma, follicular lymphoma, diffuse large B-cell lymphoma, acute lymphoblastic leukemia and others. In 2021, hematological malignancies segment is expected to dominate the CAR-T cell therapy treatment market because yescarta accounts the major revenue in the market and the follicular lymphoma is the major indication for yescarta.
  • On the basis of end user, the CAR-T cell therapy treatment market is segmented into hospitals, specialty clinics and others. In 2021, hospitals segment is dominating the CAR-T cell therapy treatment market because CAR-T cell therapy required highly trained professionals with advanced technology laboratories. 
  • On the basis of distribution channel, the CAR-T cell therapy treatment market is segmented into hospitals pharmacy and others. In 2021, hospitals pharmacy segment is expected to dominate the CAR-T cell therapy treatment distribution channel because hospitals pharmacy are the central part of the hospitals, all the infusion related and medication related delivery sold by the pharmacy department.

CAR-T Cell Therapy Treatment Market Country Level Analysis

The CAR-T cell therapy treatment market is analyzed and market size information is provided on based on the country, product, structure, targeted antigens, brand, therapeutic application, end user and distribution channel as referenced above.

The countries covered in the Europe CAR-T cell therapy treatment market report are the Germany, U.K., France, Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, and Rest of Europe.

The autologous CAR-T cells segment in Germany is dominating the Europe CAR-T cell therapy treatment market owing to prevalence of cancer.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Europe brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Rise in Awareness about Immunotherapies is boosting the CAR-T Cell Therapy Treatment Market Growth 

Рынок лечения CAR-T-клеточной терапией также предоставляет вам подробный анализ рынка для каждой страны по росту в отрасли лечения CAR-T-клеточной терапией с продажами лечения CAR-T-клеточной терапией, влиянием прогресса в технологии лечения CAR-T-клеточной терапией и изменениями в регуляторных сценариях с их поддержкой рынка лечения CAR-T-клеточной терапией. Данные доступны за исторический период с 2011 по 2019 год.

Анализ конкурентной среды и доли рынка терапии CAR-T-клетками

Конкурентная среда рынка лечения клеточной терапией CAR-T содержит подробную информацию по конкурентам. Включены следующие сведения: обзор компании, финансовые показатели компании, полученный доход, рыночный потенциал, инвестиции в исследования и разработки, новые рыночные инициативы, производственные площадки и объекты, сильные и слабые стороны компании, запуск продукта, испытания продуктов, одобрения продуктов, патенты, широта и дыхание продукта, доминирование приложений, кривая жизненной линии технологий. Приведенные выше данные относятся только к фокусу компании, связанному с рынком лечения клеточной терапией CAR-T.

Основными компаниями, которые участвуют в отчете о рынке лечения CAR-T-клеточной терапией, являются Autolus, Amgen Inc., bluebird bio, Inc., Adaptimmune Therapeutics plc., Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc, AbbVie Inc., Novartis AG, Kite Pharma (дочерняя компания Gilead Sciences, Inc.), Cellectis, TC BIOPHARM, Celyad Oncology и другие отечественные и мировые игроки. Аналитики DBMR понимают конкурентные преимущества и предоставляют конкурентный анализ для каждого конкурента отдельно.  

 Многие запуски продуктов и соглашения также инициируются компаниями по всему миру, что также ускоряет развитие рынка лечения с использованием CAR-T-клеток.

Например,

  • В декабре 2020 года Atara Biotherapeutics, Inc. начала сотрудничать с Bayer AG для разработки CAR T-клеточной терапии с мезотелином для лечения солидных опухолей. Согласно соглашению, компания уделяет особое внимание разработке ATA2271 для лечения злокачественной плевральной мезотелиомы и немелкоклеточного рака легких. Это сотрудничество ускорило исследования и разработки компании для ATA2271 и позволило ей стать ведущим производителем аллогенной CAR-T-клеточной терапии.

Сотрудничество, запуск продукции, расширение бизнеса, награды и признание, совместные предприятия и другие стратегии участников рынка расширяют возможности компании на рынке лечения с использованием CAR-T-клеток, что также дает организациям возможность улучшить свое предложение по лечению с использованием CAR-T-клеток. 

SKU-

Get online access to the report on the World's First Market Intelligence Cloud

Sample Image Click on image to enlarge
  • Интерактивная панель анализа данных
  • Панель анализа компании для возможностей с высоким потенциалом роста
  • Доступ аналитика-исследователя для настройки и запросов
  • Анализ конкурентов с помощью интерактивной панели
  • Последние новости, обновления и анализ тенденций
  • Используйте возможности сравнительного анализа для комплексного отслеживания конкурентов
Запросить демонстрацию

Содержание

  1. introduction
    1. OBJECTIVES OF THE STUDY
    2. MARKET DEFINITION
    3. OVERVIEW of EUROPE CAR-T cell therapy treatment MARKET
    4. LIMITATIONs
    5. MARKETS COVERED
  2. MARKET SEGMENTATION
    1. MARKETS COVERED
    2. geographical scope
    3. years considered for the study
    4. currency and pricing
    5. DBMR TRIPOD DATA VALIDATION MODEL
    6. MULTIVARIATE MODELLING
    7. PRODUCT LIFELINE CURVE
    8. primary interviews with key opinion leaders
    9. DBMR MARKET POSITION GRID
    10. vendor share analysis
    11. MARKET product COVERAGE GRID
    12. secondary sourcEs
    13. assumptions
  3. EXECUTIVE SUMMARY
  4. premium insight
  5. Epidemiology
  6. Pipeline analysis
  7. Market Overview
    1. Drivers
      1. increase in usage of CAR-T CELL THERAPY for the treatment of cancer and infectious diseases
      2. increasing prevalEnce of cancer
      3. rise in awareness about immunotherapies
      4. increasing investment in research and development
      5. adoption of CAR-T cell therapy treatment in Emerging markets
    2. restraints
      1. adverse side effects of therapies
      2. high cost associated with therapies
      3. logistic challenge associated with CAR-T therapies
      4. availability of alternatives for tumor treatment
    3. opportunities
      1. presence of pipeline producTs
      2. strategiC initiatives by market players
      3. Rise in expenditure in healthcare sector
    4. challenges
      1. long approval time for immunotherapies
      2. lack of skilled professionals
  8. IMPACT OF COVID-19 ON EUROPE CAR-T CELL THERAPY TREATMENT MARKET
    1. IMPACT ON PRICE
    2. IMPACT ON DEMAND
    3. IMPACT ON SUPPLY CHAIN
    4. STRATEGIC DECISION FOR MANUFACTURERS
    5. CONCLUSION
  9. Europe CAR-T Cell Therapy Treatment MARKET, BY PRODUCT
    1. overview
    2. Autologous CAR-T Cells
    3. Allogeneic CAR-T Cells
  10. Europe CAR-T CELL THERAPY TREATMENT MARKET, BY Structure
    1. overview
    2. First Generation CAR-T Cells
    3. Second Generation CAR-T Cells
    4. Third Generation CAR-T Cells
    5. Fourth Generation CAR-T Cells
  11. Europe CAR-T CELL THERAPY TREATMENTMARKET, BY Targeted Antigens
    1. overview
    2. Antigens on Hematologic Malignancies
      1. Cluster of Differentiation-19 (CD-19)
      2. Cluster of Differentiation-30 (CD-30)
      3. Cluster of Differentiation-22 (CD-22)
      4. Cluster of Differentiation-20 (CD-20)
      5. Cluster of Differentiation-33 (CD-33)
    3. Antigens on Solid Tumors
      1. Human Epidermal Growth Factor Receptor-2 (HER-2)
      2. Epidermal Growth Factor Receptors Variant III (EGFRV-III)
      3. Mesothelin (MSLN)
      4. Prostate-Specific Membrane Antigen (PSMA)
      5. Interleukin-13RA2 (IL13RA2)
      6. Disialoganglioside 2 (GD2)
      7. Glypican-3 (GPC3)
      8. Others
    4. OTHERS
  12. Europe CAR-T cell therapy treatment MARKET, BY brand
    1. overview
    2. yescarta
    3. KYMRIAH
    4. TECARTUS
    5. others
  13. Europe CAR-T cell therapy treatment MARKET, BY therapeutic application
    1. overview
    2. Follicular Lymphoma
    3. Diffuse Large B-Cell Lymphoma
    4. Acute Lymphoblastic Leukaemia (ALL)
    5. Mantle Cell Lymphoma
    6. Multiple Myeloma
    7. Hematologic Malignancies
      1. Leukemia
      2. Lymphoma
      3. Myeloma
      4. Others
    8. Lung Cancer
    9. Chronic Lymphocytic Leukemia
    10. Gastric Cancer
    11. Pancreatic Cancer
    12. Breast Cancer
    13. others
  14. Europe CAR-T cell therapy treatment MARKET, BY end user
    1. overview
    2. hospitals
    3. Specialty Clinics
    4. others
  15. Europe CAR-T cell therapy treatment MARKET, BY distribution channel
    1. overview
    2. hospital Pharmacy
    3. others
  16. Europe CAR-T cell therapy treatment market by geography
    1. EUROPE
      1. germany
      2. u.k
      3. France
      4. Italy
      5. Spain
      6. NETHERLANDS
      7. Russia
      8. Switzerland
      9. Belgium
      10. Turkey
      11. Austria
      12. Norway
      13. Hungary
      14. Lithuania
      15. Ireland
      16. Poland
      17. Rest of Europe
  17. Europe CAR-T Cell Therapy Treatment Market: COMPANY landscape
    1. company share analysis: europe
  18. swot analysis
  19. company profile
    1. kite pharma (A subsidiary of GILEAD SCIENCES, INC.)
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. company share analysis
      4. PRODUCT PORTFOLIO
      5. RECENT DEVELOPMENTS
    2. Novartis AG
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. company share analysis
      4. PRODUCT PORTFOLIO
      5. RECENT DEVELOPMENTS
    3. Abbvie inc.
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    4. Adaptimmune Therapeutics plc
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    5. Amgen Inc.
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PIPELINE PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    6. Atara Biotherapeutics, Inc.
      1. COMPANY SNAPSHOT
      2. PIPELINE PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENTS
    7. aurora biopharmA
      1. COMPANY SNAPSHOT
      2. PIPELINE PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENTS
    8. Autolus
      1. COMPANY SNAPSHOT
      2. PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENTS
    9. Bellicum Phamaceuticals, Inc.
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    10. BioAtla Inc.
      1. COMPANY SNAPSHOT
      2. PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENTS
    11. bluebird bio, inc.
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    12. Bristol-Myers Squibb Company
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    13. carina biotech
      1. COMPANY SNAPSHOT
      2. PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENTS
    14. cartherics pty ltd
      1. COMPANY SNAPSHOT
      2. PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENTS
    15. cartesian therapeutics, inc.
      1. COMPANY SNAPSHOT
      2. PIPELINE PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENTS
    16. cellectis SA
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    17. celyad oncology SA
      1. COMPANY SNAPSHOT
      2. PIPELINE PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENTS
    18. Johnson & Johnson Services, Inc.
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    19. sorrento therapeutics, INC.
      1. COMPANY SNAPSHOT
      2. PIPELINE PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENTS
    20. tc biopharm Limited
      1. COMPANY SNAPSHOT
      2. PIPELINE PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENTS
    21. tessa therapeutics ltd.
      1. COMPANY SNAPSHOT
      2. PIPELINE PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENTS
    22. tmunity therapeutics
      1. COMPANY SNAPSHOT
      2. PIPELINE PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENTS
    23. mustang bio
      1. COMPANY SNAPSHOT
      2. PIPELINE PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENTS
    24. Xyphos (A Subsidiary of Astellas Pharma Inc.)
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PIPELINE PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    25. ziopharm oncology, inc.
      1. COMPANY SNAPSHOT
      2. PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENTS
  20. questionnaire
  21. related reports

Список таблиц

TABLE 1 Europe CAR-T cell therapy treatment Market, pipeline analysis

TABLE 2 Below provided are the alternative chemotherapies of CAR-T cell therapy:

TABLE 3 TOTAL HEALTH SPENDING BY THE U.S. (2015-2016)

TABLE 4 Europe CAR-T CELL THERAPY TREATMENTMarket, By MOLECULE, 2019-2028 (USD Million)

TABLE 5 Europe Autologous CAR-T Cells in CAR-T CELL THERAPY TREATMENTMarket, By Region, 2017-2028 (USD Million)

TABLE 6 Europe Allogeneic CAR-T Cells in CAR-T CELL THERAPY TREATMENTMARKET, By Region, 2019-2028 (USD Million)

TABLE 7 Europe CAR-T CELL THERAPY TREATMENTMarket, By Structure, 2019-2028 (USD Million)

Celyad is engaged in the manufacturing of CYAD-211, a first generation CAR-T cell therapy expressing BCMA targeting chimeric antigen receptor which interferes with the expression of the CD3ζ of T cell receptor complex.

TABLE 8 Europe First Generation CAR-T Cells in CAR-T CELL THERAPY TREATMENT Market, By Region, 2019-2028 (USD Million)

TABLE 9 Europe Second Generation CAR-T Cells in CAR-T CELL THERAPY TREATMENT Market, By Region, 2019-2028 (USD Million)

TABLE 10 Europe Third Generation CAR-T Cells in CAR-T CELL THERAPY TREATMENT Market, By Region, 2019-2028 (USD Million)

TABLE 11 Europe Third Generation CAR-T Cells in CAR-T CELL THERAPY TREATMENT Market, By Region, 2019-2028 (USD Million)

TABLE 12 Europe CAR-T CELL THERAPY TREATMENTMarket, By targeted antigens, 2019-2028 (USD Million)

TABLE 13 Europe Antigens on Hematologic Malignancies in CAR-T CELL THERAPY TREATMENT Market, By Region, 2019-2028 (USD Million)

TABLE 14 Europe Antigens on Hematologic Malignancies in CAR-T CELL THERAPY TREATMENT Market, By Antigens on Hematologic Malignancies, 2019-2028 (USD Million)

TABLE 15 Europe Antigens on Solid Tumors in CAR-T CELL THERAPY TREATMENTMarket , By Region, 2017-2028 (USD Million)

TABLE 16 Europe Antigens on Solid Tumors in CAR-T CELL THERAPY TREATMENT Market, By Antigens on Solid Tumors, 2019-2028 (USD Million)

TABLE 17 Europe others in CAR-T CELL THERAPY TREATMENTMarket , By Region, 2017-2028 (USD Million)

TABLE 18 Europe YESCARTA in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)

TABLE 19 Europe YESCARTA in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)

TABLE 20 Europe KYMRIAH in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)

TABLE 21 Europe TECARTUS in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)

TABLE 22 Europe others in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)

TABLE 23 Europe CAR-T cell therapy treatment Market, By therapeutic type, 2019-2028 (USD Million)

TABLE 24 Europe Follicular Lymphoma in CAR-T cell therapy treatment Market, By therapeutic type, 2017-2028 (USD Million)

TABLE 25 Europe Diffuse Large B-Cell Lymphoma in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)

TABLE 26 Europe ACUTE LYMPHOBLASTIC LEUKAEMIA (ALL) in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)

TABLE 27 Europe Mantle Cell Lymphoma in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)

TABLE 28 Europe Multiple Myeloma in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)

TABLE 29 Europe hematologic malignancies in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)

TABLE 30 Europe hematologic malignancies on Solid Tumors in CAR-T CELL THERAPY TREATMENT Market, By therapeutic application, 2019-2028 (USD Million)

TABLE 31 Europe Lung Cancer in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)

TABLE 32 Europe chronic lymphocytic leukemia in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)

TABLE 33 Europe gastric cancer in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)

TABLE 34 Europe pancreatic cancer in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)

TABLE 35 Europe breast cancer in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)

TABLE 36 Europe others in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)

TABLE 37 Europe CAR-T cell therapy treatment Market, By END USER, 2019-2028 (USD Million)

TABLE 38 Europe hospitals in CAR-T cell therapy treatment Market, By therapeutic type, 2017-2028 (USD Million)

TABLE 39 Europe specialty clinics in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)

TABLE 40 Europe others in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)

TABLE 41 Europe CAR-T cell therapy treatment Market, By distribution channel, 2019-2028 (USD Million)

TABLE 42 Europe hospital pharmacy in CAR-T cell therapy treatment Market, By distribution channel, 2017-2028 (USD Million)

TABLE 43 Europe others in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)

TABLE 44 Europe CAR-T Cell Therapy Treatment Market, By Region, 2019-2028 (USD Million)

TABLE 45 Europe CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)

TABLE 46 Europe CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)

TABLE 47 Europe CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 48 europe Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 49 Europe Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 50 Europe CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)

TABLE 51 Europe CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 52 Europe Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 53 Europe CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)

TABLE 54 Europe CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 55 Germany CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)

TABLE 56 Germany CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)

TABLE 57 Germany CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 58 Germany Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 59 Germany Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 60 Germany CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)

TABLE 61 Germany CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 62 Germany Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 63 Germany CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)

TABLE 64 Germany CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 65 U.K CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)

TABLE 66 U.K CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)

TABLE 67 U.K CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 68 U.K Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 69 U.K Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 70 U.K CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)

TABLE 71 U.K CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 72 U.K Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 73 U.K CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)

TABLE 74 U.K CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 75 FRANCE CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)

TABLE 76 FRANCE CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)

TABLE 77 FRANCE CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 78 FRANCE Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 79 FRANCE Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 80 FRANCE CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)

TABLE 81 FRANCE CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 82 FRANCE Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 83 FRANCE CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)

TABLE 84 FRANCE CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 85 ITALY CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)

TABLE 86 ITALY CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)

TABLE 87 ITALY CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 88 ITALY Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 89 ITALY Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 90 ITALY CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)

TABLE 91 ITALY CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 92 ITALY Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 93 ITALY CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)

TABLE 94 ITALY CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 95 Spain CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)

TABLE 96 SPAIN CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)

TABLE 97 SPAIN CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 98 SPAIN Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 99 SPAIN Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 100 SPAIN CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)

TABLE 101 SPAIN CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 102 SPAIN Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 103 SPAIN CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)

TABLE 104 SPAIN CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 105 netherlands CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)

TABLE 106 NETHERLANDS CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)

TABLE 107 NETHERLANDS CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 108 NETHERLANDS Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 109 NETHERLANDS Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 110 NETHERLANDS CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)

TABLE 111 NETHERLANDS CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 112 NETHERLANDS Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 113 NETHERLANDS CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)

TABLE 114 NETHERLANDS CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 115 Russia CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)

TABLE 116 RUSSIA CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)

TABLE 117 RUSSIA CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 118 RUSSIA Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 119 RUSSIA Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 120 RUSSIA CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)

TABLE 121 RUSSIA CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 122 RUSSIA Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 123 RUSSIA CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)

TABLE 124 RUSSIA CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 125 Switzerland CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)

TABLE 126 SWITZERLAND CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)

TABLE 127 SWITZERLAND CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 128 SWITZERLAND Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 129 SWITZERLAND Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 130 SWITZERLAND CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)

TABLE 131 SWITZERLAND CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 132 SWITZERLAND Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 133 SWITZERLAND CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)

TABLE 134 SWITZERLAND CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 135 belgium CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)

TABLE 136 BELGIUM CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)

TABLE 137 BELGIUM CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 138 BELGIUM Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 139 BELGIUM Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 140 BELGIUM CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)

TABLE 141 BELGIUM CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 142 BELGIUM Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 143 BELGIUM CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)

TABLE 144 BELGIUM CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 145 turkey CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)

TABLE 146 TURKEY CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)

TABLE 147 TURKEY CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 148 TURKEY Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 149 TURKEY Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 150 TURKEY CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)

TABLE 151 TURKEY CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 152 TURKEY Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 153 TURKEY CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)

TABLE 154 turkey CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 155 Austria CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)

TABLE 156 AUSTRIA CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)

TABLE 157 AUSTRIA CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 158 AUSTRIA Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 159 AUSTRIA Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 160 AUSTRIA CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)

TABLE 161 AUSTRIA CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 162 AUSTRIA Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 163 AUSTRIA CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)

TABLE 164 Austria CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 165 norway CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)

TABLE 166 NORWAY CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)

TABLE 167 NORWAY CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 168 NORWAY Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 169 NORWAY Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 170 NORWAY CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)

TABLE 171 NORWAY CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 172 NORWAY Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 173 NORWAY CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)

TABLE 174 Norway CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 175 Hungary CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)

TABLE 176 HUNGARY CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)

TABLE 177 HUNGARY CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 178 HUNGARY Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 179 HUNGARY Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 180 HUNGARY CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)

TABLE 181 HUNGARY CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 182 HUNGARY Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 183 HUNGARY CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)

TABLE 184 Hungary CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 185 Lithuania CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)

TABLE 186 LITHUANIA CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)

TABLE 187 LITHUANIA CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 188 LITHUANIA Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 189 LITHUANIA Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 190 LITHUANIA CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)

TABLE 191 LITHUANIA CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 192 LITHUANIA Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 193 LITHUANIA CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)

TABLE 194 Lithuania CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 195 Ireland CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)

TABLE 196 IRELAND CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)

TABLE 197 IRELAND CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 198 IRELAND Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 199 IRELAND Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 200 IRELAND CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)

TABLE 201 IRELAND CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 202 IRELAND Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 203 IRELAND CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)

TABLE 204 ireland CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 205 Poland CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)

TABLE 206 POLAND CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)

TABLE 207 POLAND CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 208 POLAND Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 209 POLAND Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 210 POLAND CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)

TABLE 211 POLAND CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 212 POLAND Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 213 POLAND CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)

TABLE 214 Poland CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 215 Rest of Europe CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)

Список рисунков

FIGURE 1 Europe CAR-T cell therapy treatment MARKET: SEGMENTATION

FIGURE 2 EUROPE CAR-T cell therapy treatment MARKET: DATA TRIANGULATION

FIGURE 3 Europe CAR-T cell therapy treatment Market: DROC ANALYSIS

FIGURE 4 Europe CAR-T cell therapy treatment market: Europe VS REGIONAL MARKET ANALYSIS

FIGURE 5 Europe CAR-T cell therapy treatment Market: COMPANY RESEARCH ANALYSIS

FIGURE 6 EUROPE CAR-T cell therapy treatment MARKET: MULTIVARIATE MODELLING

FIGURE 7 EUROPE CAR-T cell therapy treatment MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 8 EUROPE CAR-T cell therapy treatment MARKET: DBMR MARKET POSITION GRID

FIGURE 9 EUROPE CAR-T cell therapy treatment MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 EUROPE car-t cell therapy treatment MARKET: MARKET product COVERAGE GRID

FIGURE 11 Europe car-t cell therapy treatment market: SEGMENTATION

FIGURE 12 increasing investment in research and development is expected to drive THE Europe CAR-T cell therapy treatment market IN THE FORECAST PERIOD OF 2021 to 2028

FIGURE 13 Autologus car-t cells SEGMENT is expected to account for the largest share of the Europe CAR-T CELL THERAPY TREATMENT market in 2021 & 2028

FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGEs OF Europe CAR-T cell therapy treatment Market

FIGURE 15 New Cancer Cases Worldwide, (2018)

FIGURE 16 Europe Cancer Incidence (2018)

FIGURE 17 Cancer Death By Type (in million), world, 2017

FIGURE 18 Europe CAR-T CELL THERAPY TREATMENTmarket: BY Product, 2021

FIGURE 19 Europe CAR-T CELL THERAPY TREATMENTmarket: BY Product, 2019-2028 (USD Million)

FIGURE 20 Europe CAR-T CELL THERAPY TREATMENTmarket: BY Product, CAGR (2021-2028)

FIGURE 21 Europe CAR-T CELL THERAPY TREATMENTmarket: BY Product, LIFELINE CURVE

FIGURE 22 Europe CAR-T CELL THERAPY TREATMENTmarket: BY structure, 2021

FIGURE 23 Europe CAR-T CELL THERAPY TREATMENTmarket: BY structure, 2019-2028 (USD Million)

FIGURE 24 Europe CAR-T CELL THERAPY TREATMENTmarket: BY structure, CAGR (2021-2028)

FIGURE 25 Europe CAR-T CELL THERAPY TREATMENTmarket: BY structure, LIFELINE CURVE

FIGURE 26 Europe CAR-T CELL THERAPY TREATMENTmarket: BY targeted antigens, 2021

FIGURE 27 Europe CAR-T CELL THERAPY TREATMENTmarket: BY targeted antigens, 2019-2028 (USD Million)

FIGURE 28 Europe CAR-T CELL THERAPY TREATMENTmarket: BY targeted antigens, CAGR (2021-2028)

FIGURE 29 Europe CAR-T CELL THERAPY TREATMENTmarket: BY targeted antigens, LIFELINE CURVE

FIGURE 30 Europe CAR-T cell therapy treatment market: BY brand, 2020

FIGURE 31 Europe CAR-T cell therapy treatment market: BY brand, 2020-2028 (USD Million)

FIGURE 32 Europe CAR-T cell therapy treatment market: BY brand, CAGR (2020-2028)

FIGURE 33 Europe CAR-T cell therapy treatment market: BY brand, LIFELINE CURVE

FIGURE 34 Europe CAR-T cell therapy treatment market: BY therapeutic application, 2020

FIGURE 35 Europe CAR-T cell therapy treatment market: BY therapeutic application, 2020-2028 (USD Million)

FIGURE 36 Europe CAR-T cell therapy treatment market: BY therapeutic application, CAGR (2020-2028)

FIGURE 37 Europe CAR-T cell therapy treatment market: BY therapeutic application, LIFELINE CURVE

FIGURE 38 Europe CAR-T cell therapy treatment market: BY END USER, 2020

FIGURE 39 Europe CAR-T cell therapy treatment market: BY END USER, 2020-2028 (USD Million)

FIGURE 40 Europe CAR-T cell therapy treatment market: BY END USER, CAGR (2020-2028)

FIGURE 41 Europe CAR-T cell therapy treatment market: BY END USER, LIFELINE CURVE

FIGURE 42 Europe CAR-T cell therapy treatment market: BY distribution channel, 2020

FIGURE 43 Europe CAR-T cell therapy treatment market: BY distribution channel, 2020-2028 (USD Million)

FIGURE 44 Europe CAR-T cell therapy treatment market: BY distribution channel, CAGR (2020-2028)

FIGURE 45 Europe CAR-T cell therapy treatment market: BY distribution channel, LIFELINE CURVE

FIGURE 46 Europe CAR-T CELL THERAPY TREATMENT market: SNAPSHOT (2020)

FIGURE 47 Europe CAR-T CELL THERAPY TREATMENT market: BY COUNTRY (2020)

FIGURE 48 Europe CAR-T CELL THERAPY TREATMENT market: BY COUNTRY (2021 & 2028)

FIGURE 49 Europe CAR-T CELL THERAPY TREATMENT market: BY COUNTRY (2020 & 2028)

FIGURE 50 Europe CAR-T CELL THERAPY TREATMENT market: BY product (2021-2028)

FIGURE 51 EUROPE CAR-T Cell Therapy Treatment Market: company share 2020 (%)

View Detailed Information Right Arrow

Методология исследования

Сбор данных и анализ базового года выполняются с использованием модулей сбора данных с большими размерами выборки. Этап включает получение рыночной информации или связанных данных из различных источников и стратегий. Он включает изучение и планирование всех данных, полученных из прошлого заранее. Он также охватывает изучение несоответствий информации, наблюдаемых в различных источниках информации. Рыночные данные анализируются и оцениваются с использованием статистических и последовательных моделей рынка. Кроме того, анализ доли рынка и анализ ключевых тенденций являются основными факторами успеха в отчете о рынке. Чтобы узнать больше, пожалуйста, запросите звонок аналитика или оставьте свой запрос.

Ключевой методологией исследования, используемой исследовательской группой DBMR, является триангуляция данных, которая включает в себя интеллектуальный анализ данных, анализ влияния переменных данных на рынок и первичную (отраслевую экспертную) проверку. Модели данных включают сетку позиционирования поставщиков, анализ временной линии рынка, обзор рынка и руководство, сетку позиционирования компании, патентный анализ, анализ цен, анализ доли рынка компании, стандарты измерения, глобальный и региональный анализ и анализ доли поставщика. Чтобы узнать больше о методологии исследования, отправьте запрос, чтобы поговорить с нашими отраслевыми экспертами.

Доступна настройка

Data Bridge Market Research является лидером в области передовых формативных исследований. Мы гордимся тем, что предоставляем нашим существующим и новым клиентам данные и анализ, которые соответствуют и подходят их целям. Отчет можно настроить, включив в него анализ ценовых тенденций целевых брендов, понимание рынка для дополнительных стран (запросите список стран), данные о результатах клинических испытаний, обзор литературы, обновленный анализ рынка и продуктовой базы. Анализ рынка целевых конкурентов можно проанализировать от анализа на основе технологий до стратегий портфеля рынка. Мы можем добавить столько конкурентов, о которых вам нужны данные в нужном вам формате и стиле данных. Наша команда аналитиков также может предоставить вам данные в сырых файлах Excel, сводных таблицах (книга фактов) или помочь вам в создании презентаций из наборов данных, доступных в отчете.

Просмотр связанных страниц

Banner